Skip to main content
. Author manuscript; available in PMC: 2016 Dec 10.
Published in final edited form as: ACS Infect Dis. 2016 Oct 4;2(12):945–957. doi: 10.1021/acsinfecdis.6b00144

Figure 4.

Figure 4

Activity of tirazolopyrimidines on P. falciparum and P. vivax field isolates. A. Activity of DSM421 on P. falciparum blood stage field isolates collected from patients in Côte d’Ivoire. EC50’s were measured in the standard 72 h growth assay in RPMI media supplemented with 0.5% Albumax. Data are shown as a scatterplot of compound EC50s for individual patient isolates. AS, artesunate, CQ, chloroquine, and LUM, lumefantrine were tested as controls. Bars represent the mean. The mean ± standard deviation, number of isolates (n) and the range for each drug were as follows: DSM421 (0.023 ± 0.012, n=20, 6.9 – 48); AS (0.0038 ± 0.0039, n=18, 0.2 – 15.7); CQ (0.035 ± 0.030, n=18, 3.9–116); LUM (0.029 ± 0.031, n=7, 0.9 – 94). B. Activity of DSM421 and DSM265 on P. falciparum and P. vivax blood stage field isolates collected from patients in Papua, Indonesia. Drug efficacy was tested in a 48 h schizont maturation assay in 10% human serum based media. Bars represent the mean. Median values and ranges are reported in Table S4.